All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid).All RTX...
Sorrento Therapeutics announced the public release of the results of its’ multicenter, open-label, phase 1b study to Evaluate Safety and MTD of Epidural Resiniferatoxin injection for the treatment of intractable cancer pain, at the 14th Annual Pain Therapeutics Summit held virtually. Data was presented by Srdjan Nedeljkovic, MD, Associate Professor of Anesthesia, and Harvard Medical School/Brigham & Women's Hospital.
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences